PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
PR Newswire —
If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug...